Introduction
The significance of Fas (APO-1/CD95) expression by leukemic and other neoplastic cells, especially in regard to its prognostic and therapeutic implications, has been an active and, like other rapidly evolving areas of research, a somewhat controversial topic of investigation. Early research examined the feasibility of triggering apoptosis in tumor cells by activating Fas, while more recent studies have focused on the role of Fas and its ligand in the response of tumor cells to chemotherapy. This review will briefly discuss some of these studies and the questions they have raised.
Fas as a target for therapy
The Fas/APO-1 protein was originally identified by monoclonal antibodies (mAb) that induced rapid death of certain transformed target cells via apoptosis. 1 mice engrafted with these cells. Again, normal tissue from treated mice did not show signs of apoptotic cell death. However, anti-APO-1 failed to completely eliminate all leukemic cells, and when leukemic cells recovered from these mice after treatment were re-exposed to anti-APO-1 ex vivo, they were resistant. This led the authors to postulate that prolonged exposure to anti-APO-1 induces a partial state of resistance. An alternative explanation would be that a resistant subpopulation had been selected by the treatment.
In contrast to the above findings, Ogasawara et al 9 observed significant hepatotoxicity when testing a different anti-Fas mAb (Jo2) developed in their laboratory. When this antibody was injected intraperitoneally into BALB/c mice, a 10 g dose killed 50% of these mice within 8 h. Equal amounts of control antibody had no effect. C3H/HeJ mice, which are resistant to endotoxin, were also killed by Jo2 injection, confirming that the lethal effect of the antibody was not due to endotoxin. Furthermore, MRL-lpr/lpr mice, which are Fas-negative, were resistant to Jo2, while MRL+/+ mice were sensitive. Biochemical and histological examination indicated apoptotic liver damage as the cause of death. Subsequent studies have confirmed that the Fas antigen is expressed in developing and mature liver, and primary hepatocytes from mice and man are sensitive to Fas-mediated apoptosis. [10] [11] [12] A role for Fas in maintaining liver homeostasis has been suggested, since mice lacking Fas develop liver hyperplasia in addition to other abnormalities. 13 
Fas/Fas-L expression in drug-induced apoptosis
These findings illustrate the problematic nature of using antiFas antibody or Fas-ligand as a therapeutic agent for treatment of Fas+ tumors. However, the significance of Fas and Fasligand expression by neoplastic cells remains a subject of great interest. One reason for this is that certain Fas+ cells can be induced to express Fas-ligand, thereby becoming susceptible to autocrine suicide or induction of paracrine death in neighboring Fas+ cells. In particular, Dhein et al 14 have shown that activation-induced cell death (AICD) in peripheral T cells consequent to antigen-activation of the T cell receptor is mediated via Fas/Fas-L interaction. Following TCR stimulation, T cells express both Fas and Fas-L, which can mediate apoptosis in an autocrine or paracrine manner. In studies of T-lineage leukemia, Friesen et al 15 have provided evidence that doxorubicin and certain other chemotherapeutic agents induce apoptosis in a Fas+ T-ALL cell line (CEM) by stimulating expression of Fas-L. CEM cells that became resistant to Fas-mediated apoptosis during culture with anti-Fas antibody were also 100-fold more resistant to doxorubicin. Although this could be due to selection for cells lacking a common downstream signaling component, evidence for a more direct role of Fas/Fas-L in doxorubicin-induced apoptosis was provided by antibody-blocking experiments. Incubation of doxorubin-sensitive cells with anti-Fas F(abЈ) 2 fragments prevented Fas/Fas-L binding and rendered them doxorubicinresistant, implicating Fas-L in doxorubicin cytotoxicity. Fulda et al 16 have reported a similar involvement of Fas/Fas-L in drug-mediated apoptosis of neuroblastoma cells. These findings suggest that sensitivity to doxorubicin, at least in some neoplastic cells, is dependent on a functional Fas/Fas-L pathway.
Somewhat different results were obtained by other investigators, however. Eischen et al 17 concluded that chemotherapy-induced apoptosis is not dependent on Fas/Fas-L interaction. These investigators were unable to block etoposide-induced apoptosis by using an antagonistic anti-Fas antibody (ZB4) to block possible Fas-L binding. Furthermore, they found that Fas-resistant T-lineage leukemia (Jurkat) cells underwent apoptosis indistinguishable from that seen with Fas-sensitive parental cells after treatment with a number of different chemotherapeutic agents, including doxorubicin and etoposide. However, immunoblotting and affinity labeling experiments with Fas-sensitive cells revealed that treatment with either anti-Fas-antibody or the above drugs resulted in activation of caspases 3 (CPP32/Yama) and 7 (Mch3), followed by apoptosis. These results argue that, even though Fas/Fas-L is not directly involved in the response to the above drugs, both apoptotic pathways share common downstream effector proteases.
Similar findings with regard to common pathways of caspase activation have recently been reported by Los et al, 18 who found that treatment of CEM cells and certain solid tumor cell lines with either chemotherapeutic agents (eg doxorubicin, methotrexate) or anti-Fas antibody activated common caspases, including caspases 1 (ICE) and 3. Likewise, Fasresistant lines that failed to activate caspases following Fas triggering were cross-resistant to these drugs. In agreement with these results, Gamen et al 19 found that Fas+ T-ALL lines were protected from doxorubicin by inhibiting caspase 3 activation but not by antibody blockade of Fas-L binding, again suggesting a caspase-3-dependent, but Fas/FasL-independent, apoptotic pathway for this drug.
Fas and Bcl-2
Another area of active investigation related to common mechanisms of resistance to Fas and drug-induced apoptosis is the role of Bcl-2. Debatin and Krammer 20 reported that many Fas+ T cell ALL specimens were resistant to apoptosis mediated by the anti-APO-1 antibody, and that Fas-resistance was independent of the expression of Bcl-2 by these cells. Interestingly, incubation of resistant T-ALL cells with the protein synthesis inhibitor cycloheximide induced sensitivity to anti-APO-1 in most of these cases, suggesting that Fas-resistance was dependent on synthesis of certain protein(s) other than Bcl-2. Contrastingly, in studies with murine lymphoma cells transfected with human Fas and Bcl-2, Itoh et al 21 found that transfectants expressing Fas alone were sensitive to anti-Fas antibody, while cells that also overexpressed Bcl-2 were partially protected from apoptosis. Similarly, Mandal et al 22 found that stable expression of Bcl-2 in Fas-sensitive HeLa cells protected these cells from apoptosis following Fas triggering. Specifically, Bcl-2 blocked Fas-induced cleavage of poly(ADP-ribose) polymerase (PARP), a downstream apoptotic event resulting in activation of endonucleases and DNA fragmentation.
In our own studies of a number of ALL cell lines, 23 we have found that B cell precursor (BCP)-ALL cells as well as T-ALL cells that express Fas and lack Bcl-2 are sensitive to anti-Fas antibody. In contrast, cells that express relatively high levels of Bcl-2 (as quantitated by flow cytometry) are resistant to antiFas. Unlike Fas+/Bcl-2-/Fas-sensitive ALL cells, Fas+/Bcl-2+/Fas-resistant cells failed to activate caspase 3 (CPP32/Yama) and cleave PARP following incubation with anti-Fas antibody. Additionally, the Bcl-2-/Fas-sensitive phenotype was associated with expression of a mutant p53 gene, while the Bcl-2+/Fas-resistant phenotype was primarily wt-p53+. Taken together, these observations are consistent with the idea that Bcl-2 prevents Fas-mediated apoptosis by blocking the protease cascade at a site upstream of caspase 3. 24 Furthermore, Fas+/mutant-p53+ ALL cells lacking Bcl-2 expression may be more sensitive to Fas-induced apoptotic death than are wt-p53+/Bcl-2+ leukemic cells. The majority of these Fas-sensitive, mutant-p53+ lines have been established from pediatric patients who relapsed with refractory disease, and these cells are relatively resistant to ionizing radiation and doxorubicin (Refs 23, 25 and unpublished data); these results support the idea that response to genotoxic agents, at least in mut-p53+/Bcl-2 cells, is independent of the Fas/FasL pathway.
This review has briefly examined some of the questions concerning the role of Fas expression in leukemic and other tumor cells. Resolution of these questions and their significance for the treatment of leukemia, including a possible role for Fas in chemotherapy-induced apoptosis and as a potential target for anti-Fas directed therapy, will depend on a more detailed understanding of the mechanisms of Fas-mediated apoptosis. It seems clear that Fas/FasL and a number of chemotherapeutic agents utilize the caspase cascade as an effector of apoptosis. However, contrasting findings regarding the role of the Fas/FasL pathway in the response to chemotherapy suggests a heterogeneity in the regulation of this pathway which needs to be further explored. Similarly, the interaction between Fas and other pro-and anti-apoptotic proteins should continue to be an area of active investigation.
